Atlas Venture, a biotech venture capital firm, and Access Biotechnology, a biopharma investor, led a $60m Series B round in GRO Biosciences, a biotechnology company leveraging synthetic biology, with participation from Leaps by Bayer, Redmile Group, Digitalis Ventures and Innovation Endeavors. "GRObio has built the industry-leading platform for discovery and production of therapeutics with non-standard amino acids. The Company has a clear and differentiated path to multiple commercial opportunities, starting with the pressing unmet need in severe, refractory gout. Atlas Venture is excited to partner with this outstanding team and to bring this revolutionary technology to the clinic,” Kevin Bitterman, Atlas Venture Partner.